Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: A focus on frequency of administration

Treatments in Endocrinology

Volumn 4, Issue 3, 2005, Pages 167-175

  Guillausseau, Pierre Jean ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN DERIVATIVE; METFORMIN; SULFONYLUREA;

BLOOD ANALYSIS; BODY WEIGHT; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES CONTROL; DOCTOR PATIENT RELATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LABORATORY TEST; LIFESTYLE; MEDICAL ASSESSMENT; MEDICAL SERVICE; MEDICAL SOCIETY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT INFORMATION; PATIENT MONITORING; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SELF REPORT; URINALYSIS; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 23044452744     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200504030-00005     Document Type: Review

References (46)

1. Hippocrates. On decorum. In: Jones WH, translator. Hippocrates, with an English translation. Cambridge (MA): Harvard University Press, 1923: 267-301
2. Venturini F, Nichol MB, Sung JC, et al. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999; 33: 281-8
3. Guillausseau PJ. Influence of oral antidiabetic agents in type 2 diabetes: a survey in general practice. Diabetes Metab 2003; 29: 79-82
4. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002; 19: 279-84
5. Piette JD, Wagnet TH, Potter MB, et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004; 42: 102-9
6. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes: a longitudinal cohort study. Clin Ther 2003; 25: 2958-71
7. Bissell P, May CR, Noyce PR. From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions. Soc Sci Med 2004; 58: 851-62
8. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95: 68-71
9. Grant RW, Devita NG, Singer DE, et al. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003; 26: 1408-12
10. Penfornis A. Drug compliance in type 2 diabetes: role of drug treatment regimens and consequences on their benefits. Diabetes Metab 2003; 29: S31-7
11. Nuesch R, Schroeder K, Dieterle T, et al. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ 2001; 323: 142-6
12. Paes HP, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997; 20: 1512-7
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
14. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93
15. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 Suppl. 1: S15-35
16. American Diabetes Association. Economic cost of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-32
17. Mallion JM, Baguet JP, Siche JP, et al. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens 1997; 16 Suppl. 1: S75-80
18. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 1998; 4: 1563-8
19. Vaur L, Vaisse B, Genes N, et al. Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. Am J Hypertens 1999; 12: 374-80
20. Winkler A, Teuscher AU, Mueller B, et al. Monitoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly 2002; 132: 379-85
21. Morningstar BA, Sketris IS, Kephart GC, et al. Variations in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002; 27: 213-20
22. Rothenbacher D, Ruter G, Saam S, et al. Versorgung von Patienten mit Typ-2-Diabetes. Dtsch Med Wochenschr 2002; 127: 1183-7
23. Kardas P. The DIACOM study (Effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. In press
24. Lee VWY, Leung PY. Glycemic control and medication compliance in diabetic patients in a pharmacist-managed clinic in Hong Kong. Am J Health Syst Pharm 2003; 60: 2593-6
25. Kravitz RL, Hays RD, Sherbourne CD, et al. Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med 1993; 153: 1869-78
26. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002; 30: 71-9
27. Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in type 2 diabetes. Diabet Med 2002; 19: 685-8
28. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002; 25: 1015-21
29. Lau TL, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalisation among individuals with type 2 diabetes. Diabetes Care 2004; 27: 2149-53
30. Charpentier G, Fleury F, Dubroca I, et al. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab 2005; 31: 189-95
31. Gaede P, Beck M, Vedel P, et al. Limited impact of lifestyle education in patients with type 2 diabetes and microalbuminuria: results of a randomised intervention study. Diabet Med 2001; 18: 104-8
32. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin N Am 1997; 26: 511-22
33. Morris AD. Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educ 2001; 29: 440-6
34. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? JAMA 1989; 261: 3273-7
35. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4
36. Waeber B, Erne P, Saxenhofer H, et al. Use of drugs with more than a 24-hour duration of action. J Hypertens Suppl 1994; 12 Suppl. 8: S67-71
37. Kruse W, Rampmaier J, Ullrich G, et al. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994; 32: 452-7
38. Mounier-Vehier C, Bernaud C, Carré A, et al. Compliance and antihypertensive efficacy of amlodipine compared to nifedipine slow-release. Am J Hypertens 1998; 11: 478-86
39. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Intern Med Res 1994; 22: 266-72
40. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12
41. Kuo YF, Raji MA, Markides KS, et al. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period. Diabetes Care 2003; 26: 3054-60
42. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 2000; 320: 1373-8
43. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS no. 65). Diabet Med 2003; 20: 442-50
44. Guillausseau PJ. Observance et optimisation du traitement antidiabétique oral: etude longitudinale. Presse Med 2004; 33: 156-60
45. Sieradzki J, Kasperska-Czyzyk T, Grzeszczak W. Application of gliclazide MR in uncontrolled diabetes type 2: the treatment phase results of DINAMIC 2 study. Diabetologia Praktyczna 2003; 4: 133-6
46. Delrat P, Paraire M, Jochemsen R. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30mg modified release in healthy volunteers. Biopharm Drug Dispos 2002; 23: 151-7